Table 2. Analysis of the progression-free survival based on the WHO histology and grade of gliomas.
Histology | total | Median PFS (days) | 1-year PFS survival rate | 2-year PFS survival rate | 3-year PFS survival rate | 4-year PFS survival rate | 5-year PFS survival rate | p value |
---|---|---|---|---|---|---|---|---|
LGG | 100 | 830 | 84 | 55 | 27 | 13 | 7 | < 0.0001 |
pA | 50 | 693 | 82 | 50 | 28 | 14 | 8 | |
pO | 9 | 721 | 67 | 44 | 22 | 22 | 11 | |
pOA | 41 | 860 | 90 | 63 | 27 | 10 | 5 | |
AG | 47 | 495 | 68 | 32 | 15 | 6 | ||
pAA | 10 | 611 | 70 | 50 | 20 | 10 | ||
pAO | 5 | 792 | 100 | 60 | 40 | |||
pAOA | 32 | 398 | 63 | 22 | 9 | 6 | ||
pGBM | 64 | 394 | 52 | 16 | 6 | 2 | 2 |
Abbreviations: WHO, World Health Organization; PFS, progression-free survival; LGG, low grade glioma; pA, primary astrocytoma; pO, primary oligodendroglioma; pOA, primary oligoastrocytoma; AG, anaplastic glioma; pAA, primary anaplastic astrocytoma; pAO, primary anaplastic oligodendroglioma; pAOA, primary anaplastic oligoastrocytoma; pGBM, primary glioblastoma.